понедельник, 31 октября 2016 г.

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for...

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for...


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that an abstract regarding MediciNova's ongoing clinical trial of MN-166 in ALS has been accepted for oral presentation at the 27th International Symposium on ALS/MND to be held December 7-9, 2016 in Dublin, Ireland.



from Biotech News